Mabwell (Shanghai) Bioscience Co., Ltd. (2493)

Overview

Mabwell (Shanghai) Bioscience Co., Ltd. represents a forefront entity in the biopharmaceutical sector, focusing extensively on the domain of biological products. Rooted in Shanghai, China, since its inception in 2017, the company has admirably extended its services and products across the global landscape. Mabwell’s innovations are tailored towards the advancement of treatments in several critical health areas including auto-immune diseases, oncology, ophthalmologic conditions, infectious diseases, as well as metabolic disorders. The firm’s pursuits in research and development, manufacturing, and the commercialization of these biological products underscore its commitment to addressing complex medical challenges on an international scale.

Products and Services

• JUNMAIKANG (Autoimmune Adalimumab Injection):

A prime offering for auto-immune disorders, JUNMAIKANG represents Mabwell's stride towards mitigating diseases characterized by the immune system attacking the body's own cells. This product underscores the company’s prowess in addressing autoimmune challenges.

• Oncology Products:
• 9MW2821 and 6MW3211 (Phase II): These candidates are part of Mabwell’s oncology pipeline, currently advancing through phase II clinical trials, aiming to offer new hope in the fight against cancer.
• 9MW2921, 9MW3811, and 7MW3711 (Phase I): Early-stage investigational drugs, these are undergoing phase I clinical trials, signifying the initial steps in their journey to potentially become cancer treatments.
• 8MW0511 (Phase III): Further along in development, this candidate is in phase III clinical trial, representing a critical stage before potential approval for cancer therapy.
• Autoimmune Products:
• 9MW1911 and 9MW3811 (Phase I): Undergoing phase 1 clinical trials, these products aim at tackling autoimmune diseases, contributing to Mabwell's diverse portfolio in managing such disorders.
• Metabolic Products:
• MAILISHU and 9MW3011: These offerings indicate Mabwell’s efforts in addressing various metabolic disorders, conditions that affect the body's ability to convert food into energy.
• Ophthalmology Candidates:
• 9MW0813 and 9MW0211 (Phase III): In phase III clinical trials, these ophthalmology candidates highlight Mabwell's commitment to combating eye diseases and conditions with innovative treatments.
• Infectious Product Candidate:
• 9MW1411: Embodying Mabwell’s venture into infectious diseases, this product candidate underscores the company's dedication to developing therapies for infectious ailments.